Drug
Dupilumab
Dupilumab: highest development phase Post-Market, developed by Regeneron, Sanofi. 7 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Regeneron, Sanofi
Trials
| Drug | Phase | Indication |
|---|---|---|
| Dupilumab NCT07905547 | Post-Market | Atopic Dermatitis |
| Dupilumab NCT02612454 | Phase 3 | Atopic Dermatitis |
| Dupilumab Prefilled Syringe NCT07309614 | Phase 3 | Asthma Control |
| Dupilumab (SAR231893/REGN668) NCT03560466 | Phase 3 | Asthma |
| dupilumab NCT04206553 | Phase 2/3 | Bullous Pemphigoid |
| Dupilumab NCT03682770 | Phase 2 | Peanut Allergy |
| Dupilumab NCT02210780 | Phase 2 | Atopic Dermatitis |
Latest
No recent events.
Follow Dupilumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.